Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis
Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis
复制标题
DOI：
10.1080/16078454.2020.1766865
复制
发表时间：
2020-01-01
期刊：
影响因子：
1.9
通讯作者：
Ye, Qian-Ling
中科院分区：
文献类型：
--
作者：
Song, Ming-Zhu;Mao, Yan-Mei;Ye, Qian-Ling
背景：碱性成纤维细胞生长因子（bFGF）在急性髓系白血病（AML）的发病机制中起重要作用。在未经治疗的AML患者中，循环中bFGF的水平是否升高仍不清楚。为了获得更明确的评价，进行了荟萃分析。材料和方法：我们检索了PubMed、Embase、科克伦图书馆、中国知网（CNKI）、万方和VIP数据库，以查找可能符合条件的文章。通过随机效应模型，使用森林图显示联合效应值和95%置信区间（CI）。根据样本量、样本类型和地区进行亚组分析。所有统计学分析均在STATA12.0软件中进行。结果如下：排除不符合纳入标准的文章后，本次荟萃分析纳入了11项符合纳入条件的研究。总体而言，AML患者的bFGF循环水平可能较高（SMD = 1.15，95% CI：0.35-1.94）。敏感性分析结果表明，该方法稳定性好。此外，修剪和填充分析表明，发表偏差的影响很小，结果相对稳健。此外，N < 30组、血清组和亚洲组患者的bFGF水平均高于其他亚组（P均< 0.05）。结论：目前的荟萃分析结果显示，AML患者循环中bFGF水平较高，且与样本类型、样本量和地区有关。考虑到bFGF在AML中可能的致病作用，针对bFGF的药物开发对于AML患者是非常有希望的。
Background: Basic fibroblast growth factor (bFGF) plays an important role in the pathogenesis of acute myeloid leukemia (AML). Whether the levels of circulating bFGF are increased or not in untreated AML patients is still not clear. In order to acquire a more definite evaluation, a meta-analysis was performed. Material and methods: We searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases for possible eligible articles. Forest plot was used to present the combined effect values and 95% confidence intervals (CI) through the random-effect model. Subgroup analysis was performed based on sample size, sample type, and region. All statistical analysis was performed in STATA12.0 software. Results: After excluding the articles that did not meet the inclusion criteria, 11 studies that met the inclusion conditions were included in this meta-analysis. Overall, AML patients probably had higher circulating levels of bFGF (SMD = 1.15, 95% CI: 0.35-1.94). The results of sensitivity analysis indicated that the results were stable. Moreover, the trim and fill analysis showed that publication bias had little effect and the results were relatively robust. In addition, AML patients with N < 30 group, serum group, and Asia group (all P < 0.05) had higher circulating bFGF levels, whereas other subgroups showed no significant change. Conclusion: The results of current meta-analysis revealed that AML patients had higher circulating bFGF levels, and it was associated with sample type, sample size, and region. Considering the possible pathogenic role of bFGF in AML, drug development targeting bFGF is very promising for AML patients.